Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.

Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.

US mRNA specialist Moderna today announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

The US Food and Drug Administration (FDA) has approved updated mRNA vaccines from Moderna and Pfizer/BioNTech that protect against Covid-19, despite a broader policy shift shunning the modality in the ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...

Recent CDC rule changes make all people six months and older eligible for vaccinations against COVID-19; where to find shots ...

Moderna (MRNA) announced preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE, which targets the LP.8.1 variant of SARS-CoV-2 to ...

Moderna said its updated mNexspike Covid-19 vaccine demonstrated a strong immune response against the dominant LP.8.1 variant, after previously saying its other Covid-19 vaccine, Spikevax, also ...